(Q37864159)

24 August 2017

1 reference

title

Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies (English)

1 reference

24 August 2017

2

1 reference

24 August 2017

Giovanna Pepe

4

0 references

Lidija Antunovic

object named as

Lidija Antunovic

5

0 references

author name string

Egesta Lopci

1

1 reference

24 August 2017

Maria Rita Castellani

3

1 reference

24 August 2017

Stefano Fanti

6

1 reference

24 August 2017

Emilio Bombardieri

7

1 reference

24 August 2017

publication date

12 April 2011

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

24 August 2017

published in

1 reference

24 August 2017

volume

38 Suppl 1

1 reference

24 August 2017

page(s)

S28-40

1 reference

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Clinical issues in antibody design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

State of the art in nuclear medicine dose assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

The impact of PET and SPECT on dosimetry for targeted radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

PET and PET/CT in pediatric oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Is PET always an advantage versus planar and SPECT imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Imaging hNET reporter gene expression with 124I-MIBG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Cloning and expression of the tumor-associated antigen L6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Combined modality radioimmunotherapy. Promise and peril

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Antibodies for molecular imaging of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

High-resolution positron emission tomography of human ovarian cancer in nude rats using 124I-labeled monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Positron emission tomography of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and124iodine in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

GATE: a simulation toolkit for PET and SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: Production and reaction with cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1772-6

Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.

21 January 2018

1 reference

12 December 2020

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

1 reference

12 December 2020

MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?

1 reference

12 December 2020

Workshop on the production, application and clinical translation of ''non-standard'' PET nuclides: a meeting report

1 reference

12 December 2020

Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer

1 reference

12 December 2020

Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.

1 reference

12 December 2020

PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma

1 reference

12 December 2020

Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.

1 reference

12 December 2020

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG

1 reference

12 December 2020

The promise of immuno-PET in radioimmunotherapy

1 reference

12 December 2020

PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124.

1 reference

12 December 2020

Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation

1 reference

12 December 2020

Meta-iodobenzylguanidine and analogues: chemistry and biology.

1 reference

12 December 2020

Preparation and in vivo study of 124I-labelled monoclonal antibody H17E2 in a human tumour xenograft model. A prelude to positron emission tomography (PET).

1 reference

12 December 2020

Targeting strategies for cancer radiotherapy

1 reference

12 December 2020

c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies

1 reference

12 December 2020

Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy

1 reference

12 December 2020

Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.

1 reference

12 December 2020

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer

1 reference

12 December 2020

124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice

1 reference

12 December 2020

Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv

1 reference

12 December 2020

Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis

1 reference

12 December 2020

Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software

1 reference

12 December 2020

High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial

1 reference

12 December 2020

Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody

1 reference

12 December 2020

The use of radioactive iodine in the treatment of Graves disease

1 reference

12 December 2020

Catecholamine Metabolism in Neuroblastoma 1 2

1 reference

12 December 2020

Specificity of radioiodinated MIBG for neural crest tumors in childhood

1 reference

12 December 2020

Localization of m-iodo(131I)benzylguanidine in neuroblastoma

1 reference

12 December 2020

RADIOACTIVE IODINE AS AN INDICATOR IN THYROID PHYSIOLOGY. V. THE USE OF RADIOACTIVE IODINE IN THE DIFFERENTIAL DIAGNOSIS OF TWO TYPES OF GRAVES' DISEASE.

1 reference

12 December 2020

A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin

1 reference

12 December 2020

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

1 reference

12 December 2020

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

1 reference

12 December 2020

Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma

1 reference

12 December 2020

Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions

1 reference

12 December 2020

Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer

1 reference

12 December 2020

Some optimisation studies relevant to the production of high-purity 124I and 120gI at a small-sized cyclotron

1 reference

12 December 2020

Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine

1 reference

12 December 2020

Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy

1 reference

12 December 2020

10.1007/S00259-011-1772-6

Identifiers

DOI

1 reference

24 August 2017

1 reference